MSDC-0602K

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Azemiglitazone potassium (MSDC-0602K) 是一种噻唑烷二酮类化合物，与 PPARγ 结合，IC50 为 18.25 μM。Azemiglitazone potassium 调节线粒体丙酮酸载体 (MPC)。Azemiglitazone potassium 可用于脂肪肝的研究，包括功能失调的脂质代谢、炎症和胰岛素抵抗。Azemiglitazone potassium 是一种胰岛素 (insulin) 增敏剂，单独或与 Liraglutide 联合使用可改善小鼠的胰岛素血症和脂肪肝疾病。

Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM. Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance. Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide.

——

Diabetic db/db and MS-NASH mice are treated with Azemiglitazone potassium by oral gavage, Liraglutide by s.c. injection, or combination Azemiglitazone potassium + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis (NASH).Animal Model:Five-week-old male db/db mice on C57BL/6J background and age/sex-matched db/+ control mice Dosage:30 mg/kg MSDC-0602K; 0.2 mg/kg Liraglutide Administration:MSDC-0602K gavage daily, Liraglutide s.c. injection every other day, or combined MSDC-0602K+ Liraglutide Result: MSDC-0602K corrected glycemia and reduced insulinemia when given alone, or in combination with Liraglutide. However, MSDC-0602K + Liraglutide combination more significantly improved glucose tolerance and liver histology.

——

Metabolic Enzyme/Protease

PPAR

PPAR

——

——

1314533-27-1

409.5

C19H16KNO5S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 250 mg/mL (610.50 mM; 超声助溶 )

COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)[N-]C(=O)S3.[K+]

——

(-20℃)

With Ice Pack

≥ 2 years